RxDoctor Payments Data

Hiroshi Ashikaga

Cardiovascular Disease · Baltimore, MDNPI 1588685176

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Abbott accounts for 72.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $30,533 and has fallen 96.0% since, to $1,211 in 2025. Among cardiovascular disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,638in general payments, 2019–2025

Across 233 payments — averaging $384.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$65K
  • Medtronic$20K
  • Boston Scientific$3K
  • Medical Device Business Services, Inc.$811
  • Biosense Webster, Inc.$251
  • Atricure, Inc.$204
  • plus $403 from 3 others
$22,013in research payments, 2019–2025

Across 9 payments — averaging $2445.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$22K

What the payments were for

  • Consulting fees$50,77057%
  • Speaking & faculty fees$10,00011%
  • Travel & lodging$19,53222%
  • Food & beverage$9,33610%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,638 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$168,244
Medicare patients
367
Services billed
1,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban162$215,373
XareltoRivaroxaban40$54,684
MultaqDronedarone Hcl14$24,350
Metoprolol Succinate150$3,280
Flecainide Acetate32$1,941
Amiodarone Hcl107$1,863
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$1,207
Atorvastatin Calcium17$434
ClopidogrelClopidogrel Bisulfate22$296
Furosemide31$119
Carvedilol14$101
Hydrochlorothiazide11$44

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →